The Role of Salivary Antioxidant Level in Polycystic Ovary Syndrome Women Under Assisted Reproductive Technology Treatment: A Case-control Study

Overview

Journal Int J Reprod Biomed

Specialty Reproductive Medicine

Date 2025 Feb 19

PMID 39968368

Authors

Narges Gholizadeh

Maryam Koopaie

Ashraf Aleyasin

Atousa Mortazavi Milani

Marziyeh Aghahosseini

Mohammad Javad Kharrazifard

Mohadeseh Bahmaee

Affiliations

Soon will be listed here.

Abstract

Background: Infertility is defined as the inability to conceive after 12 months of regular unprotected intercourse. Approximately 85% of infertile couples have an identifiable cause, one of the most common causes of infertility is polycystic ovary syndrome (PCOS). The reduction of antioxidant levels in serum and follicular fluid in infertile women compared to healthy women shows the importance of further studying these markers.

Objective: To study salivary and serum antioxidant levels in PCOS participants under assisted reproductive technology.

Materials And Methods: This case-control study was conducted on 80 women in 2 groups including normal participants as control and PCOS groups (n = 40/each). Serum and salivary antioxidant levels such as saliva superoxide dismutase (SOD), saliva anti-Müllerian hormone (AMH), serum SOD, serum total oxidant status, and serum AMH were measured.

Results: The average age of participants was 31.6 5.4 yr. In both the saliva and serum, antioxidant levels differed significantly between the PCOS and control groups. Key findings showed that the PCOS group had different antioxidant levels and higher serum AMH levels compared to the control group, with all differences being statistically significant (p 0.05).

Conclusion: Our finding underscored that saliva antioxidant levels, especially SOD, are a good marker for PCOS diagnosis. It is noninvasive, can easily be performed by the participants, and can be collected in various settings without specialized equipment.

References

Teede H, Deeks A, Moran L . Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8:41. PMC: 2909929. DOI: 10.1186/1741-7015-8-41. View

Jamil M, Debbarh H, Aboulmaouahib S, Aniq Filali O, Mounaji K, Zarqaoui M . Reactive oxygen species in reproduction: harmful, essential or both?. Zygote. 2020; 28(4):255-269. DOI: 10.1017/S0967199420000179. View

Vagios S, Sacha C, Hammer K, Dimitriadis I, James K, Bormann C . Response to ovulation induction treatments in women with polycystic ovary syndrome as a function of serum anti-Müllerian hormone levels. J Assist Reprod Genet. 2021; 38(7):1827-1833. PMC: 8324640. DOI: 10.1007/s10815-021-02217-x. View

Velthut A, Zilmer M, Zilmer K, Kaart T, Karro H, Salumets A . Elevated blood plasma antioxidant status is favourable for achieving IVF/ICSI pregnancy. Reprod Biomed Online. 2013; 26(4):345-52. DOI: 10.1016/j.rbmo.2012.12.012. View

Pekel A, Gonenc A, Turhan N, Kafali H . Changes of sFas and sFasL, oxidative stress markers in serum and follicular fluid of patients undergoing IVF. J Assist Reprod Genet. 2014; 32(2):233-41. PMC: 4354184. DOI: 10.1007/s10815-014-0396-8. View

Bizon A, Tchorz A, Madej P, Lesniewski M, Wojtowicz M, Piwowar A . The Activity of Superoxide Dismutase, Its Relationship with the Concentration of Zinc and Copper and the Prevalence of rs2070424 Superoxide Dismutase Gene in Women with Polycystic Ovary Syndrome-Preliminary Study. J Clin Med. 2022; 11(9). PMC: 9102417. DOI: 10.3390/jcm11092548. View

Azziz R, Carmina E, Chen Z, Dunaif A, Laven J, Legro R . Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2:16057. DOI: 10.1038/nrdp.2016.57. View

Venetis C, Storr A, Chua S, Mol B, Longobardi S, Yin X . What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis. Hum Reprod Update. 2023; 29(3):307-326. PMC: 10152179. DOI: 10.1093/humupd/dmac040. View

Teede H, Gibson-Helm M, Norman R, Boyle J . Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome. J Clin Endocrinol Metab. 2013; 99(1):E107-11. DOI: 10.1210/jc.2013-2978. View

10.

Mohammadi M . Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review. Int J Prev Med. 2019; 10:86. PMC: 6547785. DOI: 10.4103/ijpvm.IJPVM_576_17. View

11.

Talat A, Satyanarayana P, Anand P . Association of Superoxide Dismutase Level in Women with Polycystic Ovary Syndrome. J Obstet Gynaecol India. 2022; 72(1):6-12. PMC: 8804132. DOI: 10.1007/s13224-021-01430-z. View

12.

Lin J, Wang L . Oxidative Stress in Oocytes and Embryo Development: Implications for Systems. Antioxid Redox Signal. 2020; . DOI: 10.1089/ars.2020.8209. View

13.

Fiers T, Dielen C, Somers S, Kaufman J, Gerris J . Salivary estradiol as a surrogate marker for serum estradiol in assisted reproduction treatment. Clin Biochem. 2016; 50(3):145-149. DOI: 10.1016/j.clinbiochem.2016.09.016. View

14.

Miller N, Herzberger E, Pasternak Y, Klement A, Shavit T, Tamir Yaniv R . Does stress affect IVF outcomes? A prospective study of physiological and psychological stress in women undergoing IVF. Reprod Biomed Online. 2019; 39(1):93-101. DOI: 10.1016/j.rbmo.2019.01.012. View

15.

Li W, Liu C, Yang Q, Zhou Y, Liu M, Shan H . Oxidative stress and antioxidant imbalance in ovulation disorder in patients with polycystic ovary syndrome. Front Nutr. 2022; 9:1018674. PMC: 9650267. DOI: 10.3389/fnut.2022.1018674. View

16.

van der Ham K, Laven J, Tay C, Mousa A, Teede H, Louwers Y . Anti-müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis. Fertil Steril. 2024; 122(4):727-739. DOI: 10.1016/j.fertnstert.2024.05.163. View

17.

Becatti M, Fucci R, Mannucci A, Barygina V, Mugnaini M, Criscuoli L . A Biochemical Approach to Detect Oxidative Stress in Infertile Women Undergoing Assisted Reproductive Technology Procedures. Int J Mol Sci. 2018; 19(2). PMC: 5855814. DOI: 10.3390/ijms19020592. View

18.

Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H . Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017; 107(6):1380-1386.e1. DOI: 10.1016/j.fertnstert.2017.04.011. View

19.

Christodoulakos G, Augoulea A, Lambrinoudaki I, Sioulas V, Creatsas G . Pathogenesis of endometriosis: the role of defective 'immunosurveillance'. Eur J Contracept Reprod Health Care. 2007; 12(3):194-202. DOI: 10.1080/13625180701387266. View

20.

Chang S, Dunaif A . Diagnosis of Polycystic Ovary Syndrome: Which Criteria to Use and When?. Endocrinol Metab Clin North Am. 2021; 50(1):11-23. PMC: 7860982. DOI: 10.1016/j.ecl.2020.10.002. View